Pravastatin vs Atorvastatin: Key Differences Explained

Pravastatin and atorvastatin both lower cholesterol by blocking the same enzyme, but they differ in strength, how they move through the body, and the drugs they interact with. Atorvastatin is the more potent of the two, capable of driving LDL cholesterol down roughly twice as far at maximum doses. Pravastatin, on the other hand, is one of the mildest statins on the market and carries a notably cleaner drug-interaction profile. Those differences ripple outward into everything from side-effect patterns to who each drug suits best.

How Much Each Drug Lowers LDL Cholesterol

The gap in raw cholesterol-lowering power is substantial. In the ARBITER trial, atorvastatin reduced LDL cholesterol by about 49% after 12 months, while pravastatin managed about 27% in the same period.¹ A large network meta-analysis ranking all seven commonly used statins for LDL-lowering ability placed atorvastatin second overall (behind rosuvastatin), while pravastatin landed fifth out of seven.²

What this means in practice depends on where your LDL needs to go. If you only need a modest reduction, say around 25 to 30%, a moderate dose of pravastatin can get you there. If your target requires a steep drop of 40% or more, atorvastatin is the more likely choice. Most prescribing guidelines treat atorvastatin as a “high-intensity” statin at its top dose (80 mg) and pravastatin as a “moderate-intensity” statin at its top dose (40 mg). They’re not interchangeable milligram for milligram, so a switch from one to the other requires dose adjustment, not a simple pill swap.

Why They Behave Differently in the Body

The most fundamental difference is solubility. Atorvastatin is lipophilic, meaning it dissolves easily in fat and can slip into cells throughout the body. Pravastatin is hydrophilic, meaning it dissolves in water and tends to concentrate in the liver, the organ where cholesterol production actually matters.³ This hepatoselectivity is often cited as a theoretical advantage: if a drug mainly works where it’s needed and stays out of muscle, brain, and pancreatic tissue, it might cause fewer off-target effects. In practice, the clinical significance of this distinction is still debated, but it does have measurable consequences for drug interactions and possibly for diabetes risk.

The two drugs also have different half-lives. Atorvastatin stays active in the bloodstream for about 14 hours, while pravastatin clears out in roughly two to three hours. The longer half-life explains why atorvastatin can be taken at any time of day, whereas pravastatin is traditionally recommended at bedtime. A meta-analysis of dosing-time studies confirmed that evening dosing produced better LDL lowering for short-half-life statins like pravastatin, with the difference in LDL reduction averaging close to 10 mg/dL compared to morning dosing.⁴ Even long-half-life statins like atorvastatin showed a small advantage with evening dosing, but it’s small enough that most clinicians don’t insist on it.

Drug Interactions and the CYP3A4 Question

This is where the chemical differences translate into a real, everyday concern. Atorvastatin is broken down by a liver enzyme called CYP3A4, which also processes a long list of common medications: certain antifungals, some antibiotics, calcium channel blockers, HIV protease inhibitors, and even grapefruit juice in large amounts. When you take one of these alongside atorvastatin, the competing drug can slow down atorvastatin’s metabolism, causing it to build up in your system. In one study, the antifungal itraconazole boosted atorvastatin blood levels by about 150%, while the antibiotic clarithromycin increased them more than fourfold.⁵ Higher statin blood levels raise the risk of muscle damage and other side effects.

Pravastatin largely sidesteps this problem. In the same study, coadministration with itraconazole, verapamil, and mibefradil produced no significant changes in pravastatin’s blood levels. Clarithromycin did roughly double pravastatin exposure, but that’s modest compared to the fourfold or even tenfold jumps seen with atorvastatin and simvastatin.⁵ If you take medications that inhibit CYP3A4, or if you’re on several drugs at once, pravastatin’s neutral interaction profile is a genuine clinical advantage.

The PROVE IT Trial and Cardiovascular Outcomes

The largest head-to-head comparison of these two drugs is the PROVE IT–TIMI 22 trial, which enrolled over 4,000 patients who had just been hospitalized with an acute coronary syndrome (heart attack or severe unstable angina). Half received atorvastatin 80 mg daily, the other half pravastatin 40 mg. After two years, the rate of major cardiovascular events was 22.4% in the atorvastatin group versus 26.3% in the pravastatin group, a relative reduction of 16% in favor of atorvastatin.⁶ Follow-up analyses found that intensive atorvastatin also cut the total burden of recurrent events by about 19%.⁷

It’s worth pausing on what this trial actually shows. It compared the maximum dose of atorvastatin against the maximum dose of pravastatin, which is really a test of intensive versus moderate lipid lowering, not a fair milligram-to-milligram contest. The median LDL achieved was about 62 mg/dL in the atorvastatin arm and 95 mg/dL in the pravastatin arm.⁶ Separate analysis of C-reactive protein and LDL targets in this trial found that reaching low levels of both markers mattered more than which drug got you there.⁸ In other words, if you could get LDL low enough with any statin, the benefit would be similar. Atorvastatin’s advantage is that it can reach those lower targets where pravastatin cannot.

A gender-specific analysis of PROVE IT found that women treated with atorvastatin had a 25% relative reduction in cardiovascular events compared to pravastatin, while men had a 14% relative reduction. The absolute benefit was actually larger for women in this trial, which was unusual enough to be noteworthy given that women have historically been underrepresented in statin research.⁹

The REVERSAL Trial and Plaque Progression

The REVERSAL trial asked a different question: does intensive lipid lowering actually slow the buildup of plaque in coronary arteries? Using intravascular ultrasound, researchers measured changes in atheroma (plaque) volume over 18 months. In the pravastatin arm, plaque grew by about 2.7%. In the atorvastatin arm, plaque essentially held steady (a change of −0.4%).¹⁰ Again, this was maximum-dose atorvastatin against maximum-dose pravastatin, so it reflects the ceiling of what each drug can achieve. The takeaway was that more aggressive LDL lowering can halt the physical progression of coronary artery disease, not just reduce event rates on paper.

Muscle Side Effects

Muscle complaints are the most common reason people stop taking statins, and a natural question when comparing two of them is whether one is easier on your muscles. The evidence here is reassuring for both: a network meta-analysis of over 240,000 participants across 135 randomized trials found no statistically significant difference between any individual statins for muscle symptoms, muscle pain, outright muscle damage, or the severe breakdown known as rhabdomyolysis.¹¹ The same analysis found that lipophilic statins as a class were not associated with a higher rate of muscle problems than hydrophilic ones. In controlled trials, at least, the lipophilic-versus-hydrophilic distinction doesn’t predict who gets sore muscles.

That said, dose matters. Higher doses of atorvastatin were associated with more discontinuations in a separate large meta-analysis.¹² If you’re on atorvastatin 80 mg and experiencing muscle issues, switching to a lower dose or to a different statin like pravastatin is a reasonable conversation to have with your doctor. The underlying muscle risk appears to be a class effect shared by all statins, but pushing to maximum dose amplifies it.

Diabetes Risk

All statins nudge blood sugar upward to some degree, but the effect isn’t uniform across the class. Lipophilic statins like atorvastatin can enter pancreatic beta cells more easily and may impair insulin secretion by interfering with calcium channels involved in the release process. A real-world cohort study found that atorvastatin significantly increased the risk of new-onset diabetes compared to non-use, with the researchers pointing to its lipophilic nature and resulting extrahepatic effects as a plausible explanation.¹³

Pravastatin, being hydrophilic, is generally regarded as one of the statins least likely to raise blood sugar. Some researchers have speculated that hydrophilic statins spare the pancreas by staying largely in the liver. However, the lipophilicity story doesn’t explain everything neatly, since rosuvastatin (which is also hydrophilic) has shown a dose-dependent association with new diabetes in some studies.¹⁴ If you’re at elevated risk for diabetes or already have prediabetes, the choice between these two drugs deserves a specific conversation about metabolic effects, rather than defaulting to the most potent option.

Liver Safety and Switching

Liver enzyme elevations are an uncommon but monitored side effect of statin therapy. A case report documented a patient who developed a sharp rise in liver transaminases on atorvastatin, then was switched to pravastatin with no recurrence of the problem.¹⁵ The proposed explanation, again, relates to metabolism: because atorvastatin relies on CYP3A4 and pravastatin does not, the two drugs have different hepatic toxicity profiles. For patients with chronic liver conditions or those taking other CYP3A4-dependent medications, pravastatin may carry less hepatic risk. This doesn’t mean atorvastatin is dangerous to the liver in general, but it does mean that liver enzyme trouble on one statin doesn’t necessarily mean all statins are off the table.

Effects Beyond LDL

Both drugs lower total cholesterol, but their effects on other lipid markers diverge in interesting ways. In a double-blind comparison, atorvastatin lowered apolipoprotein B (a marker of the number of atherogenic particles in the blood) by about 27%, compared to 16% with pravastatin. Atorvastatin also produced larger reductions in triglyceride-rich particles. Pravastatin, however, raised apolipoprotein A-I (a protein on “good” HDL particles) more than atorvastatin did, with an 11% increase versus 7%.¹⁶ Both effects are considered beneficial, but they reflect different strengths.

One lipid marker that moves in a less welcome direction on statin therapy is lipoprotein(a), or Lp(a), an independent cardiovascular risk factor. In the PROVE IT trial, atorvastatin raised Lp(a) levels by about 24%, while pravastatin raised them by about 12%.¹⁷ This difference wasn’t consistent across all trials, and the REVERSAL study showed no significant gap between the two. Still, for patients with elevated Lp(a) at baseline, it’s a data point worth knowing, especially as newer therapies targeting Lp(a) directly become available.

Cognitive Concerns and the Blood-Brain Barrier

Because lipophilic statins can cross the blood-brain barrier more readily than hydrophilic ones, there has been ongoing interest in whether atorvastatin might affect cognition differently than pravastatin. The FDA added a general cognitive-side-effect label to all statins in 2012, but the evidence behind it remains thin. A narrative review noted that the brain maintains its own cholesterol production largely independent of circulating blood cholesterol, and that the blood-brain barrier limits how much any statin actually reaches brain tissue.¹⁸ The theoretical concern is real, in the sense that a lipophilic molecule does have an easier path into the central nervous system, but clinical studies have not consistently shown meaningful cognitive differences between lipophilic and hydrophilic statins.

Coenzyme Q10

A persistent worry in statin discussions is whether the drugs deplete coenzyme Q10 (CoQ10), a molecule involved in cellular energy production. Because CoQ10 is made through the same biochemical pathway that statins inhibit, the concern is biologically plausible. However, a study directly comparing pravastatin and atorvastatin in healthy subjects found that neither drug significantly changed circulating CoQ10 levels, even though both successfully lowered LDL cholesterol.¹⁹ The authors concluded that at standard doses, the drugs did not meaningfully suppress CoQ10 synthesis. This doesn’t settle the question for high doses or long-term use, but it does suggest that routine CoQ10 supplementation isn’t necessarily warranted for everyone starting either drug.

Use in Children and Familial Hypercholesterolemia

Atorvastatin has been studied in children and adolescents with familial hypercholesterolemia, a genetic condition that causes dangerously high cholesterol from a young age. In a multicenter, placebo-controlled trial, atorvastatin lowered LDL by about 40% in pediatric patients over 26 weeks and was tolerated as well as placebo.²⁰ Pravastatin also has FDA approval for pediatric use in familial hypercholesterolemia, and its mild interaction profile makes it an appealing choice for younger patients who may eventually need multiple medications. For families dealing with this condition, the choice between the two often depends on how aggressively LDL needs to drop.

Cost and Availability

Both pravastatin and atorvastatin have been available as generics for years, which has dramatically leveled the price difference between them. When these drugs were still under patent, cost-effectiveness analyses showed that atorvastatin generally came out favorably because its greater potency meant fewer patients needed add-on therapies to reach their LDL goals.²¹ Generic pravastatin, meanwhile, was found to be among the cheapest options for patients who only needed moderate LDL lowering.²² Today, both generic versions are inexpensive at most pharmacies, and cost alone rarely drives the decision between them. Insurance formulary tiers can vary, though, so checking your plan’s preferred drug list is still worth doing.

How They Were Developed

Pravastatin and atorvastatin come from entirely different branches of the statin family tree. Pravastatin is derived from a natural fungal compound, compactin, which was chemically modified by microbes to produce the active drug. Atorvastatin is fully synthetic, designed in a lab to mimic the shape of the enzyme’s natural substrate while blocking it more forcefully.²³ This difference in origin partly explains the potency gap: the synthetic statins (atorvastatin, fluvastatin, rosuvastatin) were engineered for maximum enzyme inhibition, while the fungal-derived statins (pravastatin, lovastatin, simvastatin) are limited by the molecular scaffolds nature provided. The synthetic approach allowed chemists to optimize binding to HMG-CoA reductase in ways that tweaking a fungal molecule could not easily achieve.